Posts by Christine Frankovic

Christine Frankovic currently serves in a Senior Business Development Director role at KCAS, supporting West Coast and International Accounts. Having worked in CROs since 1998, she has gathered experience throughout her career in various operations and business development/marketing roles focused in Clinical Operations, Clinical Pharmacology, Bioanalytical/Biomarker, and Central Lab/Kitting services. Prior to joining KCAS upon divestment from AAIPharma in 2009, she has previously worked at AAIPharma, Quintiles, and Hoechst Marion Roussel (now Sanofi). She received her BS in Microbiology at Kansas State University and works out of the San Francisco Bay Area.

PATTERN_BLUE_1320x780_2 Blogs
Read article KCAS Offers Adaptive, Creative, and Responsive Solutions to COVID-related Supply Chain Issues.

The benevolent COVID virus has brought our industry many “gifts.” One birthday present is like a jelly of the month club subscription, and it’s impacted all Central Labs and providers of Clinical Sample Collection Kits, without discretion: the shifting un-availability of important kit contents, like vacutainers and polypropylene tubes. While…

PATTERN_ORANGE_1320x780_2 Blogs
Read article Practical Considerations for Implementing a 20-Analyte Biomarker LC-MS/MS Assay

Biomarkers can be defined and utilized for many purposes.  There are disease biomarkers as well as mechanistic or pharmacological biomarkers.  To reduce attrition and better understand a therapeutic, it is essential to be able to monitor the effectiveness of the therapeutic during drug development. Measurement of biomarker levels related to…

PATTERN_ORANGE_1320x780_2 Blogs
Read article Bioanalytical Strategy Across the Drug Development Paradigm

At KCAS, we work with Director, VP, and C-level pharmaceutical and biotech executives that need to measure their drug or the effect of their drug in biological matrix. Many of our customers rely on…

PATTERN_ORANGE_1320x780_3 Blogs
Read article Global Clinical Sample Logistics at KCAS

If you’re running a clinical or preclinical study, there are many components that you need to think about, plan, and execute. One is “what the heck do I do with these samples we’re collecting”…

PATTERN_AMBER_1320x780_3 Blogs
Read article 505(b)(2) Drug Development: A Bioanalytical Lab’s Perspective

The 505(b)(2) drug development path, in contrast to traditional development of a new, never been approved drug (described under 505(b)(1) of the Federal Food, Drug, and Cosmetic Act) or ANDA (described under Section 505(j) of the Act) for a generic drug that is no longer under patent…